Hong Kong Stock Movement: AKESO fell 11.39%, with no significant news but showing volatility. What is driving the market sentiment?

Hong Kong Stock Movement Akeso, down 11.39%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Sihuan Pharmaceutical down 8.49%. Based on recent news, On April 20, Zhitong Finance reported that the MSCI China Healthcare Index rose 12.3%, outperforming the MSCI China Index by 13.6%. The Chinese government work report lists biomedicine as an emerging pillar industry, and under policy catalysis, the sector's risk appetite has been restored. Sihuan Pharmaceutical was recommended as a buy, with a target price of HKD 34.87. This news failed to boost the stock price, which instead fell due to market concerns about the effectiveness of policy implementation. On April 20, Huigang Communications pointed out that breakthroughs in AI pharmaceutical technology and the overseas expansion of Chinese innovative drugs form a dual resonance, accelerating the industry's fundamentals. Nevertheless, the market remains skeptical about the speed of policy dividend release in the short term, affecting Sihuan Pharmaceutical's stock performance. On April 20, CMB International rated Sihuan Pharmaceutical as a buy, with a target price of HKD 34.87. However, concerns among investors about the overall high valuation of the pharmaceutical sector intensified, putting pressure on the stock price. The pharmaceutical sector's policy dividends are being released, and risk appetite is being restored. Innovent Biologics down 4.31%. Based on recent key news: On April 21, Innovent Biologics announced a partnership between San Francisco and Suzhou aimed at strengthening its drug development and distribution in oncology, cardiovascular, and metabolic therapies. This collaboration may attract market attention to its future growth potential, but it failed to boost the stock price in the short term. On April 20, CMB International released a research report indicating that the MSCI China Healthcare Index's risk appetite has been restored under policy catalysis and rated Innovent Biologics as a "buy," with a target price of HKD 113.86. However, the market's response to short-term policy impacts has been cautious, leading to a decline in the stock price. On April 20, Huigang Communications reported that the Chinese government work report lists biomedicine as an emerging pillar industry, indicating that policy dividends will continue to be released. Despite a positive long-term outlook, short-term market volatility still affects Innovent Biologics' stock price. The valuation repair window for the innovative drug sector is emerging. Rongchang Biologics down 5.63%, with a trading volume of HKD 190 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Market Capitalization in the Industry BeiGene down 0.11%. Based on recent key news: On April 21, BeiGene, as the first international innovative pharmaceutical company to achieve profitability, was included in the top ten heavy positions, demonstrating its competitiveness in the innovative drug field. This combination has both certainty and growth potential, attracting market attention, yet the stock price still experienced a slight decline. Data source: Wind On April 22, the financial report of HengRui Medicine showed its profitability, but the market held a cautious attitude towards its capital dividend strategy, affecting the overall market sentiment of the innovative drug sector. Although BeiGene performed well in terms of profitability, the liquidity issues within the industry still put pressure on its stock price. Data source: Jiemian News On April 21, the valuation of the China Securities Hong Kong Stock Connect Innovative Drug Index fell to a historically low level, indicating a valuation cost-effectiveness, but concerns about market liquidity have not been completely eliminated, affecting the stock performance of BeiGene. Data source: Wind The valuation repair window of the innovative drug sector is emerging